Health authorities are calling for stricter regulations concerning nicotine pouches due to concerns over their marketing tactics, which they describe as appealing to younger audiences and easily accessible online. The Australian Medical Association (AMA) has urged the government and enforcement agencies to address existing loopholes that permit unapproved nicotine products to circulate in the market without oversight.
AMA’s Vice President, Associate Professor Julian Rait, emphasised that despite nicotine pouches lacking any approved therapeutic indication in Australia, they are marketed with attractive branding targeted at youth and are readily available for purchase online. Research indicates that nicotine absorption from these pouches can be on par with that of a cigarette, with some products containing as much as 150mg of nicotine.
Rait cautioned that regulators should take immediate action before the use of these pouches becomes widespread in Australia. He highlighted potential health risks associated with nicotine pouches, including mouth and gum irritation, nausea, headaches, and elevated blood pressure. The AMA pointed out that there are currently no approved nicotine pouches on the Australian Register of Therapeutic Goods (ARTG), implying that they should not be available through standard retail channels.
Furthering their recommendations, Rait affirmed the AMA’s support for proposed changes by the Therapeutic Goods Administration (TGA) aimed at restricting access to unapproved nicotine pouches through existing purchase pathways. The association also noted the alarming rise in sales of these unregulated products, underscoring deficiencies in government regulations regarding synthetic nicotine.
Professor Rait argued that without robust, neutral regulations and consistent national enforcement, suppliers would continue to exploit legislative grey areas. He called for enhanced protective measures, including effective online monitoring, child-proof packaging, clear health warnings, and improved tracking of adverse events related to these products.
This advocacy for increased regulation coincides with recent legislative changes in Britain, where new laws now prevent children aged 17 and under from ever legally purchasing cigarettes. UK officials also gained enhanced powers to control the flavours, packaging, and display of vaping and nicotine products to reduce their appeal among minors.
As discussions around nicotine pouch regulation intensify, the AMA continues to highlight the urgent need for a proactive approach to prevent potential health risks associated with these products.